Zura Bio Ltd. ZURA
Super Investor & Insider
| Data filing | Data op. | Insider | Ruolo | Tipo | Prezzo | Quantità | Valore |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-02-26 | Ai Biotechnology Llc | 10% | Acquisto | $6.25 | +2,000,000 | $12.5M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Zura Bio Ltd. is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company focuses on advancing a pipeline that includes tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF, currently in Phase 2 trials such as TibuSH…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees30
TickerZURA
Statistics
Market Cap$346.8M
Revenue (TTM)$0
Net Income-$68.7M
Net Margin—
EPS$-1.06
P/E7.95
P/S—
P/B1.55
EV/EBITDA-1.37
ROE-41.0%
Dividend Yield—
Price$3.65
Data: Twelve Data · Revenue = mcap / P/S